Oral GLP-1 Competitive Assessment: Pills vs Injections
Evaluating oral peptide and small-molecule approaches in the GLP-1 class.
Published Aug 12, 2024 · Updated Aug 15, 2024 · Last reviewed Aug 15, 2024
Direct answer
Oral semaglutide, orforglipron, danuglipron, and GSBR-1290 each offer distinct efficacy, tolerability, and dosing trade-offs.
Key takeaways
- Oral semaglutide is approved but requires daily fasting administration.
- Small-molecule oral GLP-1R agonists may achieve higher oral bioavailability.
- Lotiglipron discontinuation signals the need for careful liver enzyme monitoring.
Oral delivery remains a strategic goal for incretin therapies. Rybelsus uses the SNAC absorption enhancer to deliver oral semaglutide, but fasting requirements and variable exposure limit adoption. Small-molecule oral GLP-1R agonists such as orforglipron, danuglipron, and GSBR-1290 promise simpler manufacturing and dosing. Phase 2 data suggest meaningful HbA1c and weight reductions, though GI tolerability and liver safety require scrutiny after Pfizer discontinued lotiglipron for asymptomatic transaminase elevations. The winning oral profile will balance efficacy, once-daily dosing, safety, and cost.
About this report
- Author
- Dr. Michael Patel, Healthcare Equity Research Director
- Scientific reviewer
- Dr. Sarah Chen, Senior Biopharma Analyst
Related entities
Asset
Danuglipron
Asset
Lotiglipron
Asset
GSBR-1290
Asset
Orforglipron
Asset
Oral semaglutide
Company
Eli Lilly
Company
Novo Nordisk
Company
Pfizer
Company
Structure Therapeutics
Trial
NCT05564117
Trial
Pfizer-lotiglipron-Ph2
Trial
StructureTx-GSBR1290-Ph1
Trial
Lilly-orforglipron-Ph3
Target
GLP-1R
Indication
Type 2 diabetes
Indication
Obesity
Deal
Eli Lilly and Company / Chugai Pharmaceutical Co., Ltd.
Deal
Novo Nordisk A/S / Emisphere Technologies Inc.
Catalyst
Phase 2 obesity readout expected second half of 2024.
Catalyst
Pfizer expects to advance danuglipron once-daily formulation into phase 3 in 2025.